Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TLX3
REST API REST API
Homo sapiens
TLX3 is differentially expressed in 115 experiments: 56 organism parts: bone marrow, cerebellum, ... (54 more);, 85 disease states: normal, acute lymphoblastic leukemia, ... (83 more);, 24 cell types 127 cell lines 13 compound treatments and 56 other conditions.
Synonyms RNX, HOX11L2
Orthologs TLX3 (Danio rerio)   TLX3_CHICK (Gallus gallus)   TLX3 (Bos taurus)   Tlx3 (Rattus norvegicus)   Tlx3 (Mus musculus)   C15 (Drosophila melanogaster)   TLX3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term neuron differentiation, protein binding, regulation of transcription, DNA-dependent, cell fate specification, sequence-specific DNA binding, multicellular organismal development, nucleus, central nervous system development, neuron migration, respiratory gaseous exchange, negative regulation of neuron differentiation, regulation of respiratory gaseous exchange by neurological system process, neuron fate specification, sequence-specific DNA binding transcription factor activity
InterPro Term Homeobox, Homeobox_eu
UniProt Accession O43711
Search EB-eye ENSG00000164438
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-TABM-145, ... (14 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-22152, E-GEOD-19639, E-GEOD-24147, E-GEOD-2450, ... (14 experiments)

Factor Value U/D Experiments
MHHPREB1
1
E-MTAB-37
MC116
1
E-MTAB-37
RL952
1
E-MTAB-37
SNU16
1
E-MTAB-37
NCIH1666
1
E-MTAB-37
HL-60
1
E-MTAB-37
121 more value(s).


Cell type

studied in E-AFMX-5, E-GEOD-20033, E-GEOD-3920, E-GEOD-5099, E-TABM-130, ... (16 experiments)

Factor Value U/D Experiments
mesenchymal stem cell
2
E-GEOD-9894, E-MEXP-466
2
E-TABM-145, E-TABM-130
B cell
2
1
E-GEOD-13987
bronchial epithelial
1
E-AFMX-5
CD16+ dendritic cell
1
E-TABM-34
LCC
1
E-GEOD-19188
18 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-19743, E-AFMX-5, E-GEOD-15960, E-MEXP-2069, ... (24 experiments)

Factor Value U/D Experiments
normal
3
6
E-GEOD-6338, E-TABM-666, E-MEXP-2069, E-GEOD-5370, E-GEOD-10927, ... (9 experiments)
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
Raji Burkitt's lymphoma
1
E-AFMX-5
Duchenne muscular dystrophy
1
E-GEOD-3307
carcinoma
1
E-MTAB-37
79 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-1432, E-GEOD-5824, E-MEXP-1335, E-GEOD-5099, ... (7 experiments)

Factor Value U/D Experiments
none
2
E-GEOD-5824, E-GEOD-1432
dimethyl sulfoxide
6
1
E-GEOD-5824
interferon-gamma
1
E-GEOD-1432
placebo
1
E-MEXP-1335
control
25
1
E-GEOD-3284
no estradiol
1
E-GEOD-20081
7 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-18995

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73

Genotype
studied in E-GEOD-22056, E-GEOD-17476, E-TABM-321

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-666, E-GEOD-19519, E-GEOD-16363, E-GEOD-20505, ... (17 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-GEOD-12108, E-GEOD-9723

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19246

RNAi
studied in E-GEOD-5823, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.47 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM